Vivos Inc. (Trading symbol OTCMKTS:RDGL) is committed to providing shareholders with complete, up-to-the-minute information about the
company. Within this section of our website, you'll find Press Releases, Financial Information, Board of Directors, Committee Composition, Governance Documents, and other corporate information.
Thank you for your past and continued support investing in Vivos Inc., and for supporting our mission of developing technologies that will improve human life.
Vivos Inc. (OTCMKTS:RDGL) is a late stage development company engaged primarily in the development of brachytherapy devices for therapeutic applications. RDGL's focus is
on transitioning to full operations upon receipt of expected FDA clearance for its patented brachytherapy cancer product, Yttrium-90 RadioGel™.
– Mike Korenko - CEO